Device Trial Radar · NCT03230175
Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)
Last checked: Nov 19, 2026Latest source record: Jun 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Oct 4, 2017
Primary completion
Jan 10, 2019
Study completion Apr 1, 2019
Sponsor
- Lead sponsor
- BioTissue Holdings, IncNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is hypothesized that application of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer will, with concomitant management of infection, result in a higher proportion of wounds showing complete healing within 16 weeks of initiating therapy.
Conditions
- Non-healing Wound
- Non-healing Diabetic Foot Ulcer
- Diabetic Foot Infection
Interventions
TTAX01Biological
TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.
Surgical resection and debridementProcedure
Perform surgical sharp debridement in the OR, to remove: * infectious agents and biofilms (purulence), * all debris, eschar, callus and macerated non-viable tissue from the wound base, and * dead (suprabasal epidermis), scarred (elevated/edematous) and necrotic/macerated tissue from the wound edge. Surgical Resection will be performed to remove as much of the necrotic bone detected by the radiographic evidence as is appropriate.
Systemic antibioticsDrug
Six (6) weeks of systemic antibiotic therapy is required. A definitive therapy will be guided by the microbiological results based on bone biopsy.
Off-loadingDevice
Provide off-loading device appropriate to the location of wound with full length boot or total contact cast
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With Complete Wound HealingTime frame: 16-weeks
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Banner University Medical Center
Phoenix, Arizona
UCLA Olive View
Sylmar, California
University of Miami
Miami, Florida
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.